Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib

PURPOSE: EphA2 is an attractive therapeutic target due to its diverse roles in cancer growth and progression. Dasatinib is a multi-kinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are ne...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Huang, Jie, Hu, Wei, Bottsford-Miller, Justin, Liu, Tao, Han, Hee Dong, Zand, Behrouz, Pradeep, Sunila, Roh, Ju-Won, Thanapprapasr, Duangmani, Dalton, Heather J., Pecot, Chad V., Rupaimoole, Rajesh, Lu, Chunhua, Fellman, Bryan, Urbauer, Diana, Kang, Yu, Jennings, Nicholas B., Huang, Li, Deavers, Michael T., Broaddus, Russell, Coleman, Robert L., Sood, Anil K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3975695/
https://ncbi.nlm.nih.gov/pubmed/24486585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2141
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados